Mcdonald Partners LLC Lowers Stake in Illumina, Inc. (NASDAQ:ILMN)

Mcdonald Partners LLC trimmed its stake in Illumina, Inc. (NASDAQ:ILMN) by 1.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,344 shares of the life sciences company’s stock after selling 125 shares during the quarter. Mcdonald Partners LLC’s holdings in Illumina were worth $848,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. WCM Investment Management LLC boosted its stake in Illumina by 26.6% in the 4th quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock worth $551,625,000 after purchasing an additional 867,673 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in Illumina by 148.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company’s stock worth $137,735,000 after buying an additional 631,294 shares during the last quarter. Janus Henderson Group PLC lifted its stake in shares of Illumina by 40.5% in the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock worth $282,735,000 after buying an additional 625,245 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of Illumina by 116.9% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 865,546 shares of the life sciences company’s stock valued at $115,663,000 after buying an additional 466,519 shares during the last quarter. Finally, Iron Triangle Partners LP bought a new stake in shares of Illumina during the third quarter valued at approximately $57,380,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ILMN has been the topic of several analyst reports. TD Cowen cut Illumina from a “buy” rating to a “hold” rating and lowered their price objective for the company from $177.00 to $140.00 in a research report on Friday, February 7th. Stephens upped their price target on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. Piper Sandler lifted their price objective on Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. JPMorgan Chase & Co. upped their target price on shares of Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Finally, Canaccord Genuity Group dropped their price target on shares of Illumina from $145.00 to $135.00 and set a “hold” rating on the stock in a report on Friday, February 7th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $159.45.

Illumina Stock Performance

ILMN opened at $100.24 on Tuesday. The stock has a market capitalization of $15.90 billion, a price-to-earnings ratio of -13.05 and a beta of 1.10. Illumina, Inc. has a fifty-two week low of $99.35 and a fifty-two week high of $156.66. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The company has a fifty day moving average of $131.80 and a 200 day moving average of $134.75.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 12.59%. As a group, sell-side analysts forecast that Illumina, Inc. will post 4.42 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.